Last reviewed · How we verify

Paclitaxel (Pac) — Competitive Intelligence Brief

Paclitaxel (Pac) (Paclitaxel (Pac)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

marketed Taxane; microtubule stabilizer β-tubulin / microtubules Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel (Pac) (Paclitaxel (Pac)) — Aravive, Inc.. Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Paclitaxel (Pac) TARGET Paclitaxel (Pac) Aravive, Inc. marketed Taxane; microtubule stabilizer β-tubulin / microtubules
Paclitaxel (X) Paclitaxel (X) Merck Sharp & Dohme LLC phase 3 Taxane; microtubule stabilizer β-tubulin / microtubules
Abraxane (Induction) Abraxane (Induction) Celgene phase 3 Microtubule stabilizer (taxane) β-tubulin / microtubules
Nab-paclitaxel/Paclitaxel Nab-paclitaxel/Paclitaxel BioNTech SE phase 3 Microtubule stabilizer / Taxane β-tubulin / Microtubules
Continuous Docetaxel Continuous Docetaxel University of Turin, Italy phase 3 Taxane (microtubule stabilizer) β-tubulin / microtubules
Nab-paclitaxel （neoadjuvant） Nab-paclitaxel （neoadjuvant） Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University phase 3 Microtubule stabilizer / Taxane β-tubulin / Microtubules
Paclitaxel (Taxane) Paclitaxel (Taxane) Eli Lilly and Company phase 3 Taxane (microtubule-stabilizing agent) β-tubulin / microtubules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

  1. Sanofi · 2 drugs in this class
  2. Aravive, Inc. · 1 drug in this class
  3. Athenex, Inc. · 1 drug in this class
  4. Barts & The London NHS Trust · 1 drug in this class
  5. BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
  6. Bio-Thera Solutions · 1 drug in this class
  7. Dai, Guanghai · 1 drug in this class
  8. Fujian Medical University · 1 drug in this class
  9. Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
  10. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel (Pac) — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-pac. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: